• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine.

作者信息

Fong Dominic, Mair Maximilian J, Mitterer Manfred

机构信息

Department of Oncology and Haematology, Franz Tappeiner Hospital, Merano, Italy.

Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria.

出版信息

Eur J Cancer. 2021 Sep;154:4-6. doi: 10.1016/j.ejca.2021.05.036. Epub 2021 Jun 11.

DOI:10.1016/j.ejca.2021.05.036
PMID:34217909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8192959/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f22a/8192959/c38f7005cd99/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f22a/8192959/c38f7005cd99/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f22a/8192959/c38f7005cd99/gr1_lrg.jpg

相似文献

1
High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine.曾感染过新冠病毒的癌症患者在接种一剂BNT 162b2疫苗后体内出现高水平抗SARS-CoV-2 IgG抗体。
Eur J Cancer. 2021 Sep;154:4-6. doi: 10.1016/j.ejca.2021.05.036. Epub 2021 Jun 11.
2
Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan.日本医护人员接种两剂疫苗前后针对 SARS-CoV-2 核衣壳和刺突蛋白的 IgG 血清学筛查。
Tohoku J Exp Med. 2022 May 27;257(1):57-64. doi: 10.1620/tjem.2022.J017. Epub 2022 Mar 31.
3
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
4
Trajectory of SARS-CoV-2 anti-S IgG levels following transfusion and a third dose of BNT162b2 vaccine in a patient with massive postoperative bleeding: A case report.新冠病毒 IgG 抗体水平在大量术后出血患者输注后和第三剂 BNT162b2 疫苗接种后的变化轨迹：病例报告。
Int J Infect Dis. 2022 May;118:138-140. doi: 10.1016/j.ijid.2022.02.042. Epub 2022 Feb 24.
5
Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.英格兰中辉瑞和阿斯利康疫苗异源加强 COVID-19 接种方案后免疫应答的真实世界数据。
J Infect. 2022 May;84(5):692-700. doi: 10.1016/j.jinf.2022.01.038. Epub 2022 Feb 4.
6
Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.在促进健康中心工作的医护人员中，同源或异源 SARS-CoV-2 疫苗接种两剂后的抗体反应：一项前瞻性观察研究。
J Med Virol. 2022 Oct;94(10):4719-4726. doi: 10.1002/jmv.27911. Epub 2022 Jun 14.
7
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies.COVID-19 疫苗接种后在静脉注射免疫球蛋白治疗的免疫神经病变中的抗体反应。
Eur J Neurol. 2022 Nov;29(11):3380-3388. doi: 10.1111/ene.15508. Epub 2022 Aug 8.
8
Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer.甲状腺癌患者使用灭活和重组蛋白 SARS-CoV-2 疫苗的安全性和免疫原性。
Front Immunol. 2022 May 13;13:855311. doi: 10.3389/fimmu.2022.855311. eCollection 2022.
9
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.人类针对灭活的 SARS-CoV-2 疫苗的 IgM 和 IgG 反应。
Curr Med Sci. 2021 Dec;41(6):1081-1086. doi: 10.1007/s11596-021-2461-8. Epub 2021 Nov 6.
10
Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.影响实体瘤患者对 SARS-CoV-2 疫苗血清学反应的因素：一项前瞻性研究。
J Infect Chemother. 2022 Sep;28(9):1310-1316. doi: 10.1016/j.jiac.2022.05.021. Epub 2022 Jun 6.

引用本文的文献

1
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.COVID-19 疫苗在实体瘤患者中的免疫应答：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357424. doi: 10.1080/21645515.2024.2357424. Epub 2024 May 24.
2
MUW researcher of the month.当月的MUW研究员。
Wien Klin Wochenschr. 2022 Aug;134(15-16):611-613. doi: 10.1007/s00508-022-02077-0.
3
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.癌症患者的 SARS-CoV-2 疫苗免疫原性。

本文引用的文献

1
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).严重急性呼吸综合征冠状病毒 2 疫苗接种用于实体瘤患者：法国肿瘤学联合组（GCO、TNCD、UNICANCER）的回顾和观点。
Eur J Cancer. 2021 Jun;150:232-239. doi: 10.1016/j.ejca.2021.03.030. Epub 2021 Apr 1.
2
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors.BNT162b2抗SARS-CoV-2疫苗在实体瘤治疗患者中的免疫原性受损。
Ann Oncol. 2021 Aug;32(8):1053-1055. doi: 10.1016/j.annonc.2021.04.019. Epub 2021 Apr 28.
3
Trends Mol Med. 2022 Dec;28(12):1082-1099. doi: 10.1016/j.molmed.2022.07.006. Epub 2022 Aug 3.
4
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.癌症患者的 COVID-19 疫苗：免疫原性、疗效和安全性。
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. doi: 10.1038/s41571-022-00610-8. Epub 2022 Mar 11.
5
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.接受癌症治疗的实体瘤患者接种 SARS-CoV-2 mRNA 疫苗后血清转换受损。
Eur J Cancer. 2022 Mar;163:16-25. doi: 10.1016/j.ejca.2021.12.006. Epub 2021 Dec 22.
6
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
7
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.癌症患者接种第三剂抗 SARS-CoV-2 疫苗：是否需要监测体液免疫应答？一篇立场文章。
Eur J Cancer. 2022 Feb;162:182-193. doi: 10.1016/j.ejca.2021.12.011. Epub 2021 Dec 16.
8
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.癌症患者对新冠疫苗接种的抗体反应：一项系统评价
Front Oncol. 2021 Nov 4;11:759108. doi: 10.3389/fonc.2021.759108. eCollection 2021.
9
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.评估癌症患者的 COVID-19 疫苗反应：一项中期分析。
Eur J Cancer. 2021 Dec;159:259-274. doi: 10.1016/j.ejca.2021.10.013. Epub 2021 Oct 25.
10
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.血液肿瘤患者和接受 SARS-CoV-2 疫苗接种的医护人员的体液免疫反应。
JAMA Oncol. 2022 Jan 1;8(1):106-113. doi: 10.1001/jamaoncol.2021.5437.
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
癌症患者接种一剂与两剂新冠疫苗BNT162b2的安全性和免疫原性：一项前瞻性观察研究的中期分析
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
4
Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose.单剂BNT162b2疫苗接种3周后有或无既往新冠病毒病感染史的养老院居民的刺突抗体水平
JAMA. 2021 Apr 15;325(18):1898-9. doi: 10.1001/jama.2021.6042.
5
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.在先前感染过 SARS-CoV-2 的医护人员中，单次疫苗接种后的结合抗体和中和抗体滴度。
JAMA. 2021 Apr 13;325(14):1467-1469. doi: 10.1001/jama.2021.3341.